In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.
In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers. Clinical outcomes for patients without actionable mutations have shown that antiPD-L1 agents provide results comparable or better than standard of care chemotherapy regimens.
In a presentation at the 19th Annual Winter Lung Cancer Conference by Roy S. Herbst, MD, PhD, chief of medical oncology and director of the Thoracic Oncology Research Program at Yale Cancer Center in New Haven, Connecticut, reviewed the trend toward chemotherapy-free options in the first line and the focus on exploring chemoimmunotherapy treatment pathways.1
[Lung cancer] is not Hodgkins Disease, its not a disease where the chemotherapy works so well where the cells apoptose and die, Herbst said. But I think we are seeing [progress with chemotherapy-free options] in metastatic disease and certainly in early disease.
In a review of data from several studies, Herbst called attention to the baseline patient characteristics focusing on the role of PD-L1 expression on outcomes. For chemotherapy-nave patients with advanced stage disease without targetable mutations, PD-L1 expression plays a role in determining treatment pathways.
Immunotherapy is many things; [and it has] a very specific type of effect, Herbst said. Back 20 or 25 years ago, we knew about the T cell, we knew about MHC [major histocompatibility complex], we knew that the tumor cell presented a neoantigen and that interacted with the T cell. Whats new now is the whole idea of checkpoints.
Starting with data from the phase 3 KEYNOTE-024 trial (NCT0214738), Herbst pointed to the efficacy of pembrolizumab (Keytruda) vs platinum-doublet chemotherapy in patients withmetastatic nonsmall cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of at least 50%. Pembrolizumab was administered at a dose of 200 mg intravenously every 3 weeks for 2 years and chemotherapy was given for 4 to 6 cycles. Patients who progressed after chemotherapy were allowed to crossover to the pembrolizumab arm.2
The primary end point of the trial was progression-free survival (PFS). Secondary end points included overall survival (OS), overall response rate (ORR), and safety. Duration of response (DOR) was an exploratory end point. To be eligible for the trial, patients with untreated, stage IV NSCLC needed to have an ECOG performance status of 1 or less. Activating EGFR mutations or ALK translocations were not permitted. Patients with untreated brain metastases and/or active autoimmune disease requiring systemic therapy were not included.
Eligible patients (N = 305) were randomized 1:1 into the pembrolizumab or chemotherapy arms. Patients in the pembrolizumab group (n = 154) achieved a median OS of 26.3 months (95% CI, 18.3-40.4) compared with 13.4 months (95% CI, 9.4-18.3) in the chemotherapy group (HR, 0.62; 95% CI, 0.48-0.81). The 5-year OS rates were 31.9% vs 16.3%, respectively. The median PFS was 7.7 months (95% CI, 6.1-10.2) vs 5.5 months (95% CI, 4.2-6.2), respectively (HR, 0.50; 95% CI, 0.39-0.65). Three-year PFS rates were 22.8% vs 4.1%, respectively. The ORR in the pembrolizumab arm was 46.1% with a complete response (CR) rate of 4.5%, compared with 31.1% and no CRs in the chemotherapy group.
To further distill the efficacy of pembrolizumab in this patient population, investigators initiated the phase 3 KEYNOTE-042 study (NCT02220894) to asses pembrolizumab 200 mg every 3 weeks for up to 35 cycles (n = 637) vs standard-of-care (SOC) platinum-based chemotherapy for up to 6 cycles (n = 637). Patients needed to have a PD-L1 TPS of 1% or greater and an ECOG performance status of 0 or 1 to be eligible for the trial. The primary end point was OS in patients with a PD-L1 TPS at least 50%, at least 20%, and at least 1%.3
Patients who received pembrolizumab with a PD-L1 TPS of at least 50% (n = 73) had a median OS of 20.0 months (95% CI, 15.9-24.2) compared with 12.2 months (95% CI, 10.4-14.6) in the 85-patient chemotherapy group (HR, 0.68; 95% CI, 0.57-0.82). The median OS for patients with a PD-L1 TPS of at least 20% was 18.0 months (95% CI, 15.5-21.5) and 13.0 months (95% CI, 11.6-15.3) in the pembrolizumab (n = 75) and chemotherapy (n = 84) subgroups, respectively (HR ,0.75; 95% CI, 0.64-0.88). For patients with a PD-L1 TPS of at least 1%, the median OS was 16.4 months (95% CI, 14.0-19.6) in the 79-patient pembrolizumab cohort vs 12.1 months (95% CI, 11.3-13.3) in the 87-patient chemotherapy cohort (HR, 0.80; 95% CI, 0.71-0.90).
Beyond pembrolizumab, Herbst moved to data from other key trials that included agents in combination with targeted therapies.
MYSTIC (NCT02453282) was a phase 3 trial evaluating durvalumab with or without tremelimumab, a CTLA-4 antibody, compared with SOC platinum-based chemotherapy in patients with stage IV NSCLC irrespective of PD-L1 status. Patients were randomized 1:1:1 to receive durvalumab (Imfinzi) 20 mg every 4 weeks until disease progression (n = 374), tremelimumab 1 mg/kg every 4 weeks for up to 4 doses (n = 372) plus durvalumab until disease progression, or platinum-based chemotherapy (n = 372).4
Although statistical significance was not statistically significant, trends in OS among patients with PD-L1-positive tumor cells of at least 25%,favored durvalumab monotherapy over chemotherapy. Patients in this group who received durvalumab (n = 163) had a median OS of 16.3 months (95% CI, 12.2-20.8) vs 12.9 months (95% CI, 10.5-15.0) for the 162 patients treated with chemotherapy (HR, 0.76; 97.54% CI, 0.564-1.019; P = .036).
The phase 3 EMPOWER-Lung 1 study (NCT03088540) evaluated cemiplimab-rwl (Lybtayo) 350 mg monotherapy given intravenously every 3 weeks against 4 to 6 cycles of investigators choice chemotherapy in patients with untreated NSCLC with a PD-L1 expression of at least 50% on tumor cells and an ECOG performance status of 1 or lower. The trial randomized 710 patients 1:1 into the treatment arms. The primary end points of the trial were OS and PFS; secondary end points included ORR and DOR.5
In the intention-to-treat (ITT) population, the median OS was 22.1 months (95% CI, 17.7-not evaluable [NE]) in the cemiplimab arm (n = 356) vs 14.3 months (95% CI, 11.7-19.2) in the 354-patient chemotherapy group (HR, 0.68; 95% CI, 0.53-0.87; P = .0022). Among patients in the PD-L1 of at least 50% ITT population, the median OS was not reached (95% CI, 17.9-NE) compared with 14.2 months (95% CI, 11.2-17.5) in the cemiplimab and chemotherapy cohorts (HR, 0.57; 95% CI, 11.2-17.5).
Finally, Herbst called attention to data from the IMpower110 (NCT02409342) trial. The phase 3 clinical trial evaluated atezolizumab at a dose of 1200 mg every 3 weeks vs platinum-based chemotherapy in patients with chemotherapy-nave, stage IV NSCLC displaying PD-L1 expression. Patients in the experimental arm continued treatment until disease progression or loss of clinical benefit and those in the control arm continued until disease progression. The primary end point was OS in the wild-type (WT) population.6
Among patients expressing TC3 or IC3 WT, the median OS was 20.2 months (95% CI, 17.2-27.9) and 14.7 months (95% CI, 7.4-17.7) in the atezolizumab (n = 107) and chemotherapy (n = 98) arms, respectively (HR, 0.76; 95% CI, 0.54-1.09). The 12-month OS rate among the atezolizumab group was 66.1% (95% CI, 57.1%-75.1%) compared with 52.3% (95% CI, 42.2%-62.4%).
Without the adverse effect profile of chemotherapy, immunotherapy treatment options provide more manageable therapeutic options for patients with advanced disease.
With the success as monotherapy treatment options, Herbst noted that the rationale for combining immunotherapy with chemotherapy has the potential to be a pillar of care for patients. Herbst cited the separate mechanisms of action of chemotherapy and immunotherapy can synergize to reduce T-cell inhibitory substances produced by tumor and alters tumor barriers to allow for T-cell penetration.
Combination therapy reduces tumor bulk and leads to a separate mechanism of kill, Herbst said. Chemotherapy and immunotherapy are perhaps at least additive. It reduces T-cell inhibitory substances, alters tumor barriers, it kills tumor cells in a manner that might increase their immunogenicity, and it alters T-cell signaling. Its like a reset, youre resetting the tumorits a shotgun approach. Someday, well be a little more [precise] and will know exactly what we want to inhibit in the microenvironment.
KEYNOTE-189 (NCT02578680) is a phase 3 trial of first line pembrolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with stage IV non-squamous NSCLC. Patients must have an ECOG performance status of 1 or less and no actionable EGFR or ALK mutations to be eligible. The primary end points of the trial are OS and PFS; secondary end points consist of ORR, DOR, and safety.7,8
Patients in the experimental arm (n = 406) are treated with pembrolizumab 200 mg and chemotherapy every 3 weeks. The control arm (n = 206) follows the same dosing schedule, replacing pembrolizumab with placebo. Patients remain on study until disease progression or unacceptable toxicity, with crossover from placebo allowed.
Median OS was not reached (95% CI, NE-NE) in the combination group vs 11.3 months (95% CI, 8.7-15.1) in the placebo arm (HR, 0.49; 95% CI, 0.38-0.64; P < .00001). Median PFS was 8.8 months (95% CI, 7.6-9.2) and 4.9 months (95% CI, 4.7-5.), respectively (HR, 0.52; 95% CI, 0.43-0.64; P < .00001). The ORRs were 47.6% and 18.9%, respectively.
The phase 3 IMpower 150 study (NCT02366143) examined atezolizumab and bevacizumab alone and together in combination with chemotherapy in patients with stage IV or recurrent metastatic non-squamous NSCLC. Atezolizumab was given at a dose of 1200 mg intravenously every 3 weeks in combination with chemotherapy (n = 402) and in combination with bevacizumab and chemotherapy (n = 400). There was also a bevacizumab plus chemotherapy arm (n = 400).9
Concerning the coprimary end point of PFS, the atezolizumab and bevacizumab plus chemotherapy group had a median of 8.3 months (95% CI, 7.7-9.8) compared with 6.8 months (95% CI, 6.0-7.1) in the and bevacizumab plus chemotherapy group (HR, 0.59; 95% CI, 0.50-0.70; P < .0001). The follow-up was approximately 20 months and the 12-month PFS rates were 38% and 20%, respectively.
Atezolizumab and bevacizumab plus chemotherapy also outperformed bevacizumab plus chemotherapy in the other coprimary end point of OS. Median OS was 19.2 months (95% CI, 17.0-23.8) and 14.7 months (95% CI, 13.3-16.9), respectively (HR, 0.78; 95% CI, 0.64-96; P = 0.164). The 18-month OS rates were 53% and 41%, respectively.
Additionally, atezolizumab and bevacizumab plus chemotherapy was shown to increase OS regardless of PD-L1 expression status. Patients who were PD-L1 high (TC3 or IC3) achieved a median OS of 25.2 months when treated with atezolizumab and bevacizumab plus chemotherapy (n = 71) vs 15.0 months in the 65-patient bevacizumab plus chemotherapy subgroup (HR, 0.70; 95% CI, 0.43-1.13). Among the PD-L1 low patients (TC1/2 or IC1/2), median OS was 20.3 months (n = 121) and 16.4 months (n = 105), respectively (HR, 0.80; 95% CI, 0.55-1.15). PD-L1 negative patients experienced a median OS of 17.1 months (n = 167) and 14.1 months (n = 177), respectively (HR, 0.82; 95% CI, 0.62-1.08).
Continue reading here:
Immunotherapy Advances Drive Progress in Lung Cancer Treatment - OncLive
- No Rest For the Wicked | Review In Progress - XboxEra - April 27th, 2024 [April 27th, 2024]
- Maine made progress in wages and productivity, but still faces shrinking labor force - Press Herald - April 27th, 2024 [April 27th, 2024]
- The Progress Report: How 4 Schools Are Teaching Kids to Read and Seeing Success - Voice of San Diego - April 27th, 2024 [April 27th, 2024]
- PROGRESS MADE IN COLE REHAB? - Bleeding Yankee Blue - April 27th, 2024 [April 27th, 2024]
- Pollution or Progress? What's Next for LNG Development in the Rio Grande Valley - Progress Texas - April 27th, 2024 [April 27th, 2024]
- Lykos Therapeutics Makes Progress in Europe - The Dales Report - April 27th, 2024 [April 27th, 2024]
- Adelaide Film Fest Picks Five Works in Progress for Cannes Showcase, With Giant, Drafthouses Mockbuster Making the Cut (EXCLUSIVE) - Variety - April 27th, 2024 [April 27th, 2024]
- Washington says real progress needed before restoring UNRWA funding - The Times of Israel - April 27th, 2024 [April 27th, 2024]
- LIGA Provides Further Guidance: Engages Audit Firm and Making Progress in Search for CEO and Management Team - Yahoo Finance - April 27th, 2024 [April 27th, 2024]
- Forest Health Council Reports Progress Toward Community Wildfire Resiliency-Greg Felt Talks Wildfire Mitigation with ... - Heart of the Rockies Radio - April 27th, 2024 [April 27th, 2024]
- Football notes: Robert Livingston pleased with progress of CU Buffs defense - BuffZone - April 27th, 2024 [April 27th, 2024]
- Spencer Hospital Emergency Department Project Continuing to Progress - KICD - April 27th, 2024 [April 27th, 2024]
- Proof-of-Concept Exploit Released for Progress Software OpenEdge Vulnerability - The Hacker News - March 16th, 2024 [March 16th, 2024]
- Progress being made on fire alarms, Oswego town supervisor says - oswegocountynewsnow.com - March 16th, 2024 [March 16th, 2024]
- Progress on the Boyertown Express featured at Dinner - Berks Weekly - March 16th, 2024 [March 16th, 2024]
- Fire Crews Stop Forward Progress of Two-Acre Brush Fire Near Vandenberg - Santa Barbara Edhat - March 16th, 2024 [March 16th, 2024]
- Hopewell plans to install speed cameras at three city schools - Progress Index - March 16th, 2024 [March 16th, 2024]
- New numbers on progress of penny sales tax - The Post and Courier - March 16th, 2024 [March 16th, 2024]
- Long Island woman who survived acid attack continues to make progress in recovery - PIX11 New York News - March 16th, 2024 [March 16th, 2024]
- Beam marks progress toward bringing 1st-ever MLS team to San Diego - NBC San Diego - March 16th, 2024 [March 16th, 2024]
- McKone: Irish-American progress and paradoxes | Perspective | timesargus.com - Barre Montpelier Times Argus - March 16th, 2024 [March 16th, 2024]
- Big East reportedly making a lot of progress on media rights deals with CBS, Fox - Awful Announcing - March 16th, 2024 [March 16th, 2024]
- Berrien County farmers note slow progress on the new Farm Bill - News/Talk/Sports 94.9 WSJM - March 16th, 2024 [March 16th, 2024]
- END OF SESSION: Sen. Crider and Rep. Cherry reflect on progress made during the legislative session - Greenfield Daily Reporter - March 16th, 2024 [March 16th, 2024]
- Vowles being patient with Sargeant but expects to see "progress" - RaceFans - March 16th, 2024 [March 16th, 2024]
- Inflation ticked up in February, reversing some prior progress - ABC News - March 16th, 2024 [March 16th, 2024]
- Latest NEOM progress video of The Line is indicator of scale - Supercar Blondie - March 16th, 2024 [March 16th, 2024]
- Statewide Impact of Ohio Intel ProjectEvident in Initial Progress Report - Scioto Post - March 16th, 2024 [March 16th, 2024]
- SpaceX makes significant progress with third Starship orbital test flight - TechCrunch - March 16th, 2024 [March 16th, 2024]
- UPDATE: Forward progress stopped on vegetation fire near Lompoc - KSBY News - March 16th, 2024 [March 16th, 2024]
- Lady Rattlers and Diamondbacks ready to roll - Progresstimes - March 16th, 2024 [March 16th, 2024]
- SpaceX celebrates major progress on the third flight of Starship - Ars Technica - March 16th, 2024 [March 16th, 2024]
- Helldivers 2 Galactic War live map: Track status and progress with this Liberty-approved web app - Windows Central - March 16th, 2024 [March 16th, 2024]
- Pittsburgh police will only respond to calls of in-progress emergencies as part of new staffing plan - Police News - March 16th, 2024 [March 16th, 2024]
- A year of achievement, rebuilding and progress for utilities - Yoursun.com - March 16th, 2024 [March 16th, 2024]
- Trkiye: No Direct Dialogue with Damascus, No Progress in Normalization - Asharq Al-awsat - English - March 16th, 2024 [March 16th, 2024]
- A WORK IN PROGRESS | News | shelbynews.com - Shelbynews - March 16th, 2024 [March 16th, 2024]
- From recurrent networks to GPT-4: Measuring algorithmic progress in language models - Tech Xplore - March 16th, 2024 [March 16th, 2024]
- U.S. Inability To Address Nuclear Waste Harms Environmental Progress - Newsweek - March 16th, 2024 [March 16th, 2024]
- Park Progress - Greater Wilmington Business Journal - March 16th, 2024 [March 16th, 2024]
- SF supervisor to hold hearing on homeless-shelter progress | Housing | sfexaminer.com - San Francisco Examiner - March 16th, 2024 [March 16th, 2024]
- 'It's good to see progress being made on the site': Revised vision for Liberty Theater property in Libertyville - Daily Herald - March 16th, 2024 [March 16th, 2024]
- Diversity Among Emmy Winners Is a Result of Industry Progress - TheWrap - January 18th, 2024 [January 18th, 2024]
- What would Dr. King say about progress and 2024? - The Chicago Cusader - January 18th, 2024 [January 18th, 2024]
- Police: Petersburg woman reportedly used hammer to hit her boyfriend - Progress Index - January 18th, 2024 [January 18th, 2024]
- Spokane County crews make great progress ahead of another storm system - AOL - January 18th, 2024 [January 18th, 2024]
- Lady Tigers Split Last Weeks Game's Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Lexington Police Investigate Shooting at Walmart Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Scotts Hill Lions Dominated Last Week Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Older Couple Rescued From Submerged Vehicle Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Fore-ward Progress | Bintelli's new River Ridge facility to focus on making electric golf carts - WDRB - January 18th, 2024 [January 18th, 2024]
- VIDEO: Project manager gives update on Glenn McConnell Widening progress - Live 5 News WCSC - January 18th, 2024 [January 18th, 2024]
- Truck driver sentenced for trafficking cocaine to Prince George County - Progress Index - January 18th, 2024 [January 18th, 2024]
- After decades of little progress, Milwaukee begins new approach to improve lives of Black men and boys - madison365.com - January 18th, 2024 [January 18th, 2024]
- Women are bored of waiting: Slow progress on shattering the glass ceiling on company boards - I by IMD - I by IMD - January 18th, 2024 [January 18th, 2024]
- Now Accepting Applications for the 2024 Progress Software Mary Szkely Scholarship for Women in STEM - GlobeNewswire - January 18th, 2024 [January 18th, 2024]
- "Some progress made" at Onslow BOE meeting, according to number of parents - WCTI12.com - January 18th, 2024 [January 18th, 2024]
- Spokane County crews make great progress ahead of another storm system - Nonstop Local - January 18th, 2024 [January 18th, 2024]
- DeSantis took credit for Florida's progress but Iowa may have sniffed out his bravado | Opinion - Yahoo News Canada - January 18th, 2024 [January 18th, 2024]
- Has the Israeli Military Made Progress in Its Goal of Destroying Hamas? : State of the World from NPR - NPR - January 18th, 2024 [January 18th, 2024]
- Jan. 19 Panel Examines 30-Year Progress of Women in Research - Mirage News - January 18th, 2024 [January 18th, 2024]
- Ducks' Midseason Check-in: Progress, Improvement Areas & More - The Hockey Writers - January 18th, 2024 [January 18th, 2024]
- Companies are hiding their climate progress. A new report explains why. - Grist - January 18th, 2024 [January 18th, 2024]
- Lou Leonatti With Progress Mexico Gives Hospital Bankruptcy Hearing Update On AM 1340 KXEO Am I Awake Morning Show - KXEO - January 18th, 2024 [January 18th, 2024]
- Seaside Heights Wants to See Progress From Developers, Will Investigate 'Bamboo' Property - Shorebeat - January 18th, 2024 [January 18th, 2024]
- Progress over perfection: Is Coach modelling a path for fashion transformation? - Vogue Business - January 18th, 2024 [January 18th, 2024]
- Watch the video of the Edmonds armed robbery in progress - MyNorthwest - January 18th, 2024 [January 18th, 2024]
- Albemarle County house burns to the ground in late night fire - The Daily Progress - January 18th, 2024 [January 18th, 2024]
- GHDDI and Microsoft Research use AI technology to achieve significant progress in discovering new drugs to treat ... - Microsoft - January 18th, 2024 [January 18th, 2024]
- Henderson County Suspects Apprehended in Trenton Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- HCFD Reports Lowest Number of Residential Fires - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Unlocking The Future: CAGA's Progress In Web3 And Blockchain Innovation - Benzinga - January 18th, 2024 [January 18th, 2024]
- Underwhelming performance: Quarterbacks still a work in progress - Daily O'Collegian - September 3rd, 2023 [September 3rd, 2023]
- Governor Hochul Announces Progress in Increasing MTA Accessibility - ny.gov - September 3rd, 2023 [September 3rd, 2023]
- A progress report: The columnist's garden in September - Kennebec Journal and Morning Sentinel - September 3rd, 2023 [September 3rd, 2023]
- September 2023: Innovative researchers celebrate scientific ... - Environmental Factor Newsletter - September 3rd, 2023 [September 3rd, 2023]
- Progress over perfectionism - Lynn University - September 3rd, 2023 [September 3rd, 2023]
- Signs of progress on new Folsom Medical Office Building - UC Davis Health - September 3rd, 2023 [September 3rd, 2023]
- LA District FUDS team makes progress on Nellis Remedial Action ... - spl.usace.army.mil - September 3rd, 2023 [September 3rd, 2023]
- UFC Fight Night 226 winner Volkan Oezdemir pleased with progress after training with Khamzat Chimaev - Yahoo Sports - September 3rd, 2023 [September 3rd, 2023]